Tag Archives: anti infectives

Elder Pharma Reaffirms Commitment to Clear All Dues by Raising Funds Through Asset Sale or Debt or Issue of Equity

November 12, 2015 flashnewsrelease Leave a comment

* Revival in business operations likely to relieve Cash flow issues in the long term.

Mumbai, India, November 12th, 2015 — Elder Pharmaceuticals Ltd (NSE: ELDERPHARM) is committed to repaying all its creditors (secured and unsecured) by raising funds through a combination of debt, equity and asset sale. The company has already informed the exchanges regarding its intention of selling its stake in its subsidiaries in UK and Bulgaria. The company has been going through tough cash flow situations but is on the path of recovery and has substantial asset base to cover all its liabilities. Raising funds is a time consuming process and cannot be done overnight as the ‘due-diligence’ by lenders/investors takes up many months at times.

However, in recent times the company has been faced with a number of litigations – many of which are motivated – which are in effect further delaying the company’s recovery or plans to sell assets. Due to these numerous legal issues – coupled with a slow real estate market – the company has not been able to sell off its non- core assets quickly or at the right price. But the efforts continue to realize the best value for the non-core assets.

The company has also been facing a lot of negative publicity in the media, most of which is completely false, derogatory and defamatory and liable for libel. In spite of the motivated campaign to systematically tarnish its image the company enjoys a strong goodwill in market which is enabling it to revive and increase its business operations slowly but steadily. Once the company’s profitable business model reaches its earlier stage it will have sufficient cash flows to take care of its various financial needs. The only thing coming in the way are the multitude cases filed against the company.

The company and its promoters remain committed to doing their best to repay all the liabilities and to turn around the business. This commitment is not only to the investors, creditors and depositors, but also to the more than 1000 families who still believe in the Elder dream.

Elder is a major player in the anti-infectives, multi-vitamins, cardiology and skincare segments apart from the OTC segment. Although the company has sold off its 30 brands to Torrent more than a year back – it still has the international rights for these brands including Shelcal, its leading calcium supplement brand. Elder Pharma has already started exports of these brands to about 25 countries with many more on the anvil. With overwhelming response and acceptance of its product globally, the company is looking at strong prescription base in over 70 countries by March 2017. Another fast growing product is Eldervit, a prescription drug which acts as a vitamin & minerals supplement to boost energy. In addition to injection form, Elder has started making Eldervit available in capsules, gel capsules and sachet forms to make it acceptable to all age groups. The company is a market leader in wound healing and injectable B12 vitamin.

Press & Media Contact:
Mitesh M Kapadia
Sentinel Public Relations Pvt Ltd / Sentinel Advertising Services
B-603, Samajdeep, Near Bhanu Park/Seasons Restaurant
Adukia Road, Off S V Road
Kandivli (W), Mumbai 400 067 India
Mob: +91 98205 03876
Tel: (022) 28625131/32
Fax: (022) 28625133
mitesh@publicrelationindia.com
http://www.publicrelationindia.com
http://www.elderindia.com

Healthcare

Elder Pharma begins Exports of Superbrand ShelCal to more than 25 Countries, targets Rs 100 crore from Global Sales

June 25, 2015 flashnewsrelease Leave a comment

• International rights of Shelcal still with Elder after selling off brand in Domestic markets to Torrent group last year. • Elder’s wholly owned UK Subsidiary to spearhead European expansion plans.

Mumbai, India, Jun 26th, 2015 — With International rights for Shelcal still with Elder Pharmaceuticals Ltd, the company has aggressively started marketing this superbrand globally. Elder Pharma has already started exports of its leading calcium supplement brand to about 25 countries with many more on the anvil. For the year 2015-16, the company is likely to notch up sales of over Rs 25 crore and the demand is coming from some of the most unusual countries like Cambodia, Myanmar, Sri Lanka, Mauritius, Maldives, Zambia, Uganda, Yemen, Guyana, Burkinafaso, Cameroon, Congo, Ivory Coast, Gabon, Papua New Guinea, Mali, Mauritania, Niger, Senegal, Burundi, Rwanda etc. Shelcal is currently exported in the form of 250/500 mg tablets and Syrup but new line extensions are also being planned which will include Shelcal CT (Calcitrol), Shelcal OS (alpha Calcitrol) and Shelcal HD (high dosage of Vitamin D3).

Says Alok Saxena, Director, Elder Pharmaceuticals Ltd, “About a year back, Elder had sold the rights for the domestic markets of Shelcal and 30 other brands to Torrent group for a consideration of Rs 2000 crore but had retained the rights for the international markets with itself. With overwhelming response and acceptance of its product in all these markets, the company is looking at strong prescription base in over 70 countries by March 2017.”

Elder is also targeting the markets of Europe, CIS and LATAM. Shelcal’s European thrust will be spearheaded by Neutra Health plc, its wholly owned subsidiary in the UK which will market it across the EU. Sold through the ethical route, Shelcal has found support from health conscious persons as the source of calcium used in Shelcal is from ‘oyster shell’, which provides calcium in its purest form. Because of its organic origins, it is highly bio-available and gives significant increase in BMD (Bone Mineral Density). Other calcium supplements have synthetic origins and hence their contribution to BMD does not match up to Shelcal. Shelcal’s success also stems from the fact that it targets different segments like management of calcium deficiency, osteoporosis, pregnancy and lactation and is suitable for all ages.

Adds Saxena, “Earlier our production capacities were barely able to fulfill the domestic demand for Shelcal and hence we were not pursuing the exports markets in a big way. Now that we have sold the domestic rights of Shelcal we can focus on the vast global markets.” Judging by the response received so far, Elder should be able to garner a turnover of about Rs 100 crore from the International operations of Shelcal by 2017-18. The company is also looking to export another nutritional product, Thrive, a natural supplement that helps fight chronic metabolic disorders.

About Elder Pharmaceuticals Limited:
Elder Pharmaceuticals Limited [NSE: ELDERPHARM] has presence in niche therapeutic segments like Anti-INfectives, Nutraceuticals /vitamin Supplements, Dermatology and Antibiotics. It is the market leader in wound healing and injectable B12 vitamin. The company has its presence highlighted across the domestic pharmaceutical chain from in-house manufacturing, In-licensing agreements and clinical Research & Development services to gradually developing Custom Research and Manufacturing Services for advance intermediates, Active Pharmaceutical Ingredients and Dosage Formulations

Press & Media Contact:
Mitesh M Kapadia
Sentinel Public Relations Pvt Ltd / Sentinel Advertising Services
B-603, Samajdeep, Near Bhanu Park/Seasons Restaurant
Adukia Road, Off S V Road
Kandivli (W), Mumbai 400 067 India
Mob: +91 98205 03876
Tel: (022) 28625131/32
Fax: (022) 28625133
mitesh@publicrelationindia.com
http://www.publicrelationindia.com
http://www.elderindia.com

Business

Elder Pharmaceuticals Clears Pending Statutory Payments Related to TDS, PF, ESIC, MWLF etc After Witnessing Turnaround in Cash Flow Position

March 25, 2015 flashnewsrelease Leave a comment

Elder Pharmaceuticals Limited which was going through an erratic cash flow situation has made major pending statutory payments of TDS, provident fund, ESIC, Maharashtra Labour Welfare Fund (MLWF) etc to the tune of approx Rs 26 crore.

Mumbai, India, March 25th, 2015 — Elder Pharmaceuticals Limited (BSE: 532322 | NSE: ELDERPHARMEQ) which was going through an erratic cash flow situation has made major pending statutory payments of TDS, provident fund, ESIC, Maharashtra Labour Welfare Fund (MLWF) etc to the tune of approx Rs 26 crore. The company has informed the BSE & NSE to this effect.

http://www.bseindia.com/corporates/anndet_new.aspx?newsid=d6c05454-0734-4f82-b876-348077f1f915

Elder Pharmaceuticals plans to clear the backlog of other payments very soon. Elder is also in talks to raise fresh funds through a combination of debt or debt cum equity in order to improve its cash flow and performance. The company’s cash flow cycle was affected for a larger part of FY 2014-15 resulting in payments getting delayed to its various creditors and government bodies. In view of the growth in sales of its pharma & OTC products recently, the company is anticipating regular cash infusion which will contribute to its working capital, regular expenses and debt retirement needs.

Elder Pharmaceuticals is a major player in the Anti-infectives, Multi Vitamins, Cardiology and Skin care segments and is also present in the Over The Counter segment (OTC) through its products like AM/PM, Solo, Respite, Rhyme covering sectors like Oral Mouthwash, Skin Care, Nasal Decongestion, Muscle relaxants and Color Cosmetics. Elder has a prominent position in the pharma space in India and abroad with its products commanding good demand from hospitals, doctors etc. A few products like Eldervit (a nutraceutical), anti-infectives like Cefixime based Formic and Elfi, & Skin O2 (dermatology) have significant market share and are growing at over 14% annually. The company has 6 state-of-the-art production facilities across India backed by a team of over 2 dozen scientists.

Going forward, the company is embarking on a major price revamp supported by an aggressive national expansion campaign in order to garner a larger share in the domestic market. Elder’s International operations are registering steady growth and more than 40% of Elder’s revenue is likely to come from its global business. As a part of Elder’s deal with Torrent Pharmaceuticals in 2013 – which involved sale of over 30 brands and transfer of Elder’s domestic employees to Torrent – Elder shall utilize its six plants for contract manufacture of the formulations business sold to Torrent for 3 years which will fetch Elder a continous revenue stream of Rs 70 – 75 crore every year.

Elder group is targeting a turnover of about Rs 1000 cr from its domestic and international operations by FY 2017.

Healthcare

Pharma Biggies Vie for a Bigger Share of the Fast Growing Domestic Mouthwash Category in Oral Care Segment Worth Rs 600 Crore and Growing at 25% Annually

October 26, 2014 flashnewsrelease Leave a comment

* Elder Pharma relaunches AMPM Mouthwash – also introduces a Specific Mouthwash for smokers/tobacco users. * Becomes 3rd major entity after J&J and Colgate in this field; targets 5% market share.

Mumbai, India, October 24th, 2014 — With the completion of its deal with Torrent Pharma for Rs 2,000 crore involving sale of select brands, Elder Pharmaceuticals Limited (BSE: 532322 | NSE:ELDERPHARMEQ) has laid out aggressive expansion plans for achieving a turnover of Rs 1000 crore by FY 2017. In addition to its thrust on the Anti-infectives, Multi Vitamins and Skin care segments, Elder has identified the fast growing mouthwash category in the Oral c are industry as its focus area and to this effect has relaunched its famous AMPM range of mouthwash with an addition of a range for Smokers / tobacco users.

Indian oral care industry, over the last few years, has been one of the fast growing FMCG sectors. The oral care industry is segmented into five categories which include toothpaste, toothbrush, toothpowder, mouthwashes, other oral care products such as dental flosses and chewing gum.

According to Alok Saxena, Managing Director, Elder Pharma, “Among Oral Care products, the mouthwash category has seen high penetration levels with substantial market expansion even in rural and semi-urban areas. There is a major change in the consumer tastes and preferences towards easy to use oral care products in the market. Companies like Elder, focusing on advance solutions for oral health problems for the consumer, are receiving good response from the market.”

Developed by the R&D scientists at Elder Pharma in joint co-operation with practicing dentists, the new AMPM Mouthwash has as its key ingredient ‘Triclosan’, an antibacterial and antifungal agent. Triclosan has been shown to be effective in reducing and controlling bacterial contamination and fighting germs. In addition to its anti plaque and anti cavity properties, AMPM has been designed to fight gum recession, dry mouth, tobacco odour, tartar build up and tooth staining from smoking, yellowing or browning of front teeth due to exhaling tobacco smoke.

AMPM is available in 3 variants AMPM PLUS, AMPM SPECIAL and the newly launched AMPM NICOFRESH specially formulated for smokers/tobacco users. Smoking not only causes bad breath but leaves stains on teeth and leads to gum diseases. In addition to TRICLOSAN, AMPM NICOFRESH contains Sodium Perborate which helps remove smoke and tobacco tar. The oxygenating effect of NICOFRESH hits one of the most stubborn sources of sulfur-producing bacteria and stops it at its source.

Going ahead Elder is also planning to launch mouthwashes based on natural ingredients like aloe vera, green tea and probiotics under the AMPM range.

The Domestic mouthwash industry is presently valued at Rs 600 crore and growing at 25 – 30% pa. Online ecommerce players and organized retail chains are also playing a major role in the market expansion of mouthwashes as oral health & hygiene awareness increases by the day. The leader in the mouthwash category is Listerine which accounts for 70% of market share while Colgate Plax has 17% share. Elder hopes to garner a 5-7% share in the next few years.

Adds Saxena, “The industry has expanded with the introduction of innovative and condition-specific products like mouthwashes for sensitive teeth, for gum care , for discoloration of teeth, for smokers etc. Increased competition from International players has also meant reaching out to the last mile population to promote products.”

Elder’s growth strategy is to lay emphasis on expanding the brands remaining with itself post Torrent deal and strengthening them rather than launch new products. New products are also in the pipeline but will be introduced in a phased manner once the existing brands reach a critical level. Elder group’s target of Rs 1000 cr turnover by 2017 will see equal contribution from its domestic and international operations.

Healthcare

Post Torrent Deal, Elder Pharma Strengthens Presence In The Rs 4000 Crore Skin Care Sector

September 16, 2014 flashnewsrelease Leave a comment

Launches a slew of Derma products & also plans half a dozen more with a view to grab a market share of 4-5%.

Mumbai, India, September 16, 2014 — Post Torrent deal, a much leaner and better leveraged Elder Pharmaceuticals Ltd (BSE: 532322 / NSE: ELDERPHARM) has begun its ambitious foray and growth story into the Rs 4000 crore Dermatology segment. Hitherto the company had some presence in this category but with a slew of new launches it plans to grab a market share of 4-5 per cent in each sub-category. Skin care has always been a market segment characterized by several global MNCs like Unilever, P&G, Revlon, Lakme, Amway, Artistry, Olay, Garnier and L’Oreal as well as local players and thousands of small units in the unorganized category – each vying for a dominant presence through adoption of a combination of marketing strategies and product differentiation.

Amongst the new introductions of Elder are Eslite Plus, a Hydroquinone & combination cream for Skin Lightening, Ultraguard, a sunscreen containing American & European FDA standard ingredients like Tinosorb from BASF & Uvinul A Plus which make it non greasy & skin friendly as compared to other preparations, B-New, an anti aging cream for rejuvenation of dry rough skin areas, Camoflage a stretch-marks & Pregnancy line remover and Skin O2, a multi vitamin product in soft gelatin capsules for skin nourishment. Says Mr Alok Saxena, Managing Director, Elder Pharmaceuticals Ltd, “Launched through the ethical route, the initial response to these products has been encouraging and we expect these brands to contribute a combined turnover of about Rs 115-125 crore by FY16.

Also on anvil are products for lip care, hair loss, under-eye gel, face cleansers, moisturizers etc. Derma products are in demand not only for therapeutic requirements but also for lifestyle reasons enabling the skin care industry to evolve to the age of cosmetic and anti-aging treatments. Lack of comprehensive skin related treatments at medical level is one factor which is boosting the business of pharma companies and encouraging them to explore the opportunity of selling over the counter (OTC) products by bringing novel compounds in or by in-licensing international products.

Adds Saxena, “More than 80% of the cosmetics market comprises of low & medium-priced categories in terms of volume. We would be targeting the premium and economy segments through new launches and for the time being have no plans to launch products in the luxury segment.” Elder Pharma is targeting a turnover of Rs 1000 crore by 2017 with its national & International operations contributing equally. This it hopes to achieve through a combination of market positioning, mass geographical expansion, product revamps and launches in different product categories. Along with Dermatology, Elder’s major focus areas in the years to come shall be in the anti infectives, Lifestyle diseases and Neurological segments.